# EDGAR Filing Document

**Accession Number:** 0001113423
**File Stem:** 0001493152-25-023633
**Filing Date:** 2025-11
**Character Count:** 14133
**Document Hash:** 6777e48e0217571210d508787c3aa1e9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-023633.hdr.sgml**: 20251114

**ACCESSION NUMBER**: 0001493152-25-023633

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 3

**CONFORMED PERIOD OF REPORT**: 20251114

**FILED AS OF DATE**: 20251114

**DATE AS OF CHANGE**: 20251114

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38064
- **FILM NUMBER:** 251488186

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of November, 2025

Commission File Number: **001-38064**

**COSCIENS Biopharma Inc.**

(Translation of registrant's name into English)

**c/o Norton Rose Fulbright Canada, LLP, 222 Bay Street, Suite 3000, PO Box 53, Toronto ON M5K 1E7**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

On November 11, 2025, COSCIENS Biopharma Inc. (the "Company") issued a press release announcing its third quarter 2025 financial results and providing a strategic initiatives update, including its voluntarily delist from the Nasdaq Capital Market, while retaining the Company's listing on the Toronto Stock Exchange. A copy of the press release is attached to this Form 6-K as Exhibit 99.1 and is incorporated by reference herein. The press release contains forward-looking statements and includes cautionary statements identifying important factors that could cause actual results to differ materially from those in the forward-looking statements.

Exhibit 99.1 included with this Report on Form 6-K is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (No. [333-224737](https://www.sec.gov/Archives/edgar/data/1113423/000110465918031164/a18-13077_1s8.htm), No. [333-210561](https://www.sec.gov/Archives/edgar/data/1113423/000110465916109332/a16-7264_1s8.htm), No. [333-200834](https://www.sec.gov/Archives/edgar/data/1113423/000111342314000025/forms-8.htm) and No. [333-279844](https://www.sec.gov/Archives/edgar/data/1113423/000149315224022065/forms-8.htm)) (collectively, the "Registration Statements") and shall be deemed to be a part thereof from the date on which this Report on Form 6-K is furnished, to the extent not superseded by documents or reports subsequently filed or furnished. The information contained on any websites referenced in Exhibit 99.1 included with this Report on Form 6-K is not incorporated by reference or deemed to be a part of this Report on Form 6-K or any of the Registration Statements.

**Forward-Looking Statements**

The information in this Report on Form 6-K and the exhibit attached hereto and incorporated herein by reference include forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and under the provisions of Canadian securities laws. These forward-looking statements involve a number of known and unknown risks, uncertainties and other factors that could cause actual results and outcomes to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.

Forward-looking statements include, but are not limited to, those relating to the Company's expectations regarding the anticipated benefits and synergies as well as the assets, cost structure, financial position, cash flows and growth prospects of the combined company.

Risks and factors that could cause actual results or outcomes to differ materially from expectations include, among others, the following:

● the
 Company's patented technologies and value-driving products, and development thereof;

● the
 extraction, production and commercialization of active ingredients from natural sources and our ability to successfully market related
 products;

● the
 successful development and marketing of our oat-based pipeline products, including oat-beta glucan, avenanthramides and beta glucan
 from yeast, as well as such products' capability to address unmet needs within the nutraceuticals markets;

● Macrilen®
 (macimorelin) and the Company's plans in respect of same, including commercialization.

● the
 Company's business strategy;

● the
 strategic decision to sunset the Company's Amyotrophic Lateral Sclerosis (ALS), AIM Biologicals and Delayed Clearance Parathyroid
 Hormone (DC-PTH) programs ;

● the
 transition to a new presidential administration in the United States, including the potential use and effects of tariffs to address
 the administration's policy goals, could materially impact our costs and revenues, as well as the macroeconomic framework in
 which we operate.

● the
 Company's positioning in its target markets;

● the
 Company's ability to accelerate the scale-up of PGX Technology towards commercial levels;

● expectations
 for completion of the Company's Edmonton facility and Natex Termitz facility;

● pre-clinical
 and clinical studies and trials and their expected timing and results, including the potential to bring certain products to market
 following such studies and trials;

● the
 ability of our pharmaceutical therapeutic assets to address unmet medical needs across a number of indications;

● management's
 assumptions, estimates and judgements;

● liquidity
 and capital resources;

● adequacy
 of our financial resources to finance operations and expenditure requirements;

● limitations
 on internal controls over financial reporting; and

● the
 plans, objectives, future outlook and financial position of the Company in general.

Additional risk factors that could cause actual results to differ materially include those risks identified in Item 3. "Key Information – Risk Factors" contained in the Company's most recent Annual Report on Form 20-F filed with the SEC and its other filings and submissions from time to time, including those containing its quarterly and annual results, with the SEC, which are available on the Company's website located at <u>www.cosciensbio.com</u>.

Many of these risks and factors are beyond the Company's control. The Company cautions you not to place undue reliance on these forward-looking statements. All written and oral forward-looking statements attributable to the Company or persons acting on their behalf, are qualified in their entirety by these cautionary statements. Moreover, unless required by law to update these statements, the Company will not necessarily update any of these statements after the date hereof, either to conform them to actual results or to changes in their expectation.

**DOCUMENTS INDEX**

---

| | |
|:---|:---|
| **Exhibit** | **Description** |
| 99.1 | [COSCIENS Biopharma Inc. Announces Leadership Change](ex99-1.htm) |

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **COSCIENS Biopharma Inc.** | **COSCIENS Biopharma Inc.** |
| Date: November 14, 2025 | By: | */s/ Giuliano La Fratta* |
|  |  | Giuliano La Fratta |
|  |  | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**COSCIENS Biopharma Inc. Announces Leadership Change**

**TORONTO, ONTARIO, November 14, 2025** – COSCIENS Biopharma Inc. (TSX: CSCI) (FINRA: CSCIF) ("COSCIENS" or the "Company"), a life science company focused on natural ingredients and pharmaceutical solutions, announced today that Peter H. Puccetti, CFA, Chairman of the Company's board of directors (the "**Board**"), has been appointed Interim Chief Executive Officer, effective immediately. Peter succeeds Anna Biehn, who has stepped down as Chief Executive Officer.

"As the Company continues its efforts to reduce costs and streamline its organizational structure while aligning resources with key strategic priorities, the Board has determined that now is the right time to transition leadership" said Robert Seager, Chair of the Human Resources, Nominating and Governance Committee. "Peter is already deeply involved in driving the strategic reorientation of the Company and has a proven track record of creating value with similarly situated businesses. We are confident that the Company will be well-served by Peter's leadership at this critical juncture."

Mr. Puccetti said, "In my expanded role as Chairman and Interim CEO, I plan on continuing to strengthen operational performance, while working to create the conditions necessary for driving shareholder value." Mr. Puccetti continued, "On behalf of everyone at COSCIENS, I want to thank Anna for her professionalism, leadership and contributions. We wish her all the best in her future endeavors."

**About COSCIENS Biopharma Inc.**

COSCIENS is a life science company with a diverse portfolio focused on the development of natural, plant-based active ingredients and engaged in the commercialization of pharmaceutical and diagnostic products. COSCIENS' natural active ingredient business leverages the Company's proprietary manufacturing and extraction technologies to develop Avenanthramides and Beta Glucan active ingredients currently used in leading skincare brands worldwide. COSCIENS' lead pharmaceutical product Macimorelin (Macrilen; Ghryvelin), is the first and only U.S. Food and Drug Administration ("FDA") and European Medicines Agency ("EMA") approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).

The Company's common shares are listed on the Toronto Stock Exchange ("TSX") under the symbol "CSCI". The Company's common shares were assigned the trading symbol "CSCIF" by FINRA's Department of Market Operations for quoting and trading in the market for unlisted securities (i.e., the "over-the-counter market" or "OTC" market) in the United States as of September 4, 2025. For more information, please visit COSCIENS' website at <u>www.cosciensbio.com</u>.

**Forward-Looking Statements**

Certain statements in this news release, referred to herein as "forward-looking statements", constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended, and "forward-looking information" under the provisions of Canadian securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this MD&A, words such as "anticipate", "assume", "believe", "could", "expect", "forecast", "future", "goal", "guidance", "intend", "likely", "may", "would" or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Forward-looking statements in this news release include, but are not limited to, statements relating to the expectations of the interim Chief Executive Officer.

These statements are based on current expectations and assumptions, including factors or assumptions factors or assumptions that were applied in drawing a conclusion or making a forecast or projection, including assumptions based on historical trends, current conditions and expected future developments. Since forward-looking statements relate to future events and conditions, by their very nature they require making assumptions and involve inherent risks and uncertainties. The Company cautions that although it is believed that the assumptions are reasonable in the circumstances, these risks and uncertainties give rise to the possibility that actual results may differ materially from those expressed or implied by such forward-looking statements, including but not limited to the factors described in "Risks Relating to Us and Our Business" in the Company's Annual Report on Form 20-F for the year ended December 31, 2024. Given these risks, undue reliance should not be placed on these forward-looking statements, which apply only as of their dates. We disclaim any obligation to update any such risks or uncertainties or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

**Issuer Contact:**

Peter H. Puccetti

Interim CEO and Chairman of the Board

pp@cosciensbio.com

Giuliano La Fratta

Chief Financial Officer

glafratta@cosciensbio.com

**Investor Contact:**

IR@cosciensbio.com